Novel insights on CRISPR-Cas9: a game changer in genome technology
The three-dimensional structure of the genetic engineering tool is now clarified. MIMS group leader Emmanuelle Charpentier is one of the authors in the article published in Science, 6 February 2014.
After the first description in 2012 in Science, the CRISPR-Cas9 system is considered one of the most important discoveries in molecular biology in our time. Now an international team with Charpentier and her colleagues at the University in Berkeley and Zürich, described the three-dimensional structure of the complex for the first time. The structure indicates how CRISPR-Cas9 works: A so-called guide RNA acts as the decisive switch to trigger conformational rearrangement of the Cas9 enzyme and targeting of the genetic material.
Jinek M, Jiang F, Taylor D, Sternberg S, Kaya E, Ma E, Anders A, Hauer M, Zhou K, Lin S, Kaplan M, Iavarone AT, Charpentier E, Nogales E, Doudna JA (2014)
Structures of Cas9 endonucleases reveal RNA-mediated conformational activation, Science, DOI: 10.1126/science.1247997.
First description of the CRISPR-Cas9 system:
Jinek M; Chylinski K; Fonfara I, Hauer M, Doudna JA, Charpentier E (2012): A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity,SCIENCE 337 (6096):816-821.
Programmable RNA complex could speed genome editing in the lab - Publication in Science by Emmanuelle Charpentier and colleagues
Emmanuelle Charpentier, one of the scientists behind the discoveries on CRISPR-Cas9 system
2013: Signaling Breakthroughs of the Year:
"The editorial staff and distinguished scientists in the field of cell signaling nominated diverse research as advances for 2013"...
SCIENCE SIGNALING 7 (307), 7 January 2014, DOI: 10.1126/scisignal.2005013.
365 days: Nature's 10
Read the story "FENG ZHANG: DNA's master editor, Borrowing from bacteria, a biologist helps to create a powerful tool for customizing DNA.", Feng Zhang mentioned the ground breaking artilcle in 2012 by Doudna and Charpentier et al as the basis for his discoveries in the CRISPR-Cas9 field.